DMP 266 study opens at Jefferson.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage; D048588:Benzoxazines; D017322:Clinical Trials, Phase II as Topic; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage; D010078:Oxazines / Q000008:administration & dosage*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage*
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; C098320:efavirenz